Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2011
02/01/2011US7879913 treating nicotine craving or nicotine withdrawal symptoms in a human by administering a therapeutically effective dose of iptakalim hydrochloride to the human
02/01/2011US7879912 Process for preparing 3,3-diarylpropylamines
02/01/2011US7879911 2-(4-Fluorophenoxy-N-hydroxyacetamide where the "oxy" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the "lethal factor" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare
02/01/2011US7879910 Compositions and methods for promoting lush hair growth
02/01/2011US7879909 treating diabetic neuropathic foot ulcer by administering to subject an effective amount of Treprostinil or derivative or salt thereof, where derivative is sustained release, inhaled, or oral form or acid derivative, where subject has diabetic neuropathy but not peripheral vascular disease
02/01/2011US7879908 reducing number of episodes of postinfarction heart failure in patients by intravenously administering L-carnitine or salt thereof within 6 hours of onset of symptoms of acute myocardial infarction to patients in need thereof, at an initial dose of 9 grams a day, in combination with glucose solution
02/01/2011US7879907 Peroxisome Proliferator-Activated Receptor (PPAR) activators such as 3-{4-[3-(4-benzyloxy-3-methoxyphenyl)propyl]-3-butoxyphenyl}propanoic acid, used in dermatology, cosmetics, cardiovascular diseases, immunology and/or lipid metabolism
02/01/2011US7879905 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
02/01/2011US7879904 9, 10-α,α-OH-taxane analogs and methods for production thereof
02/01/2011US7879902 Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof
02/01/2011US7879901 Sublingual Formulations of Ketorolac or Salts Thereof
02/01/2011US7879900 Antiinflammatory agents; antitumor agents; Alzheimer's disease;atherosclerosis
02/01/2011US7879899 Injectable veterinary composition for small animals
02/01/2011US7879898 Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
02/01/2011US7879897 Pesticidal 5-substituted-oxyalkylamino-1-arylpyrazole derivatives
02/01/2011US7879896 Dual-acting imidazole antihypertensive agents
02/01/2011US7879895 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS)
02/01/2011US7879894 Delivery to inflamed tissue by injection, implantation, or transdermal patch; prevention of pro-inflammatory cytokines will reduce and/or alleviate inflammation of tendons and soft tissue around carpal and tarsal tunnels; reducing compression of the median nerve and posterior tibial nerve, respectively
02/01/2011US7879893 Zinc binding ligand; sustained release of insulin
02/01/2011US7879892 Anti-cancer and anti-microbial oxazolidinones
02/01/2011US7879891 Caspase inhibitor prodrugs
02/01/2011US7879890 hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis
02/01/2011US7879889 Therapeutic use of acylaminothiazole derivatives
02/01/2011US7879888 Thiazole derivatives and use thereof
02/01/2011US7879887 such as 2-(4-chloro-3-hydroxyphenylamino)-N-(6H-pyrazolo[4',3':3,4]benzo[1,2-d]thiazol-2-yl)-acetamide, having antitumor activity, particularly dual inhibitory activity on Aurora kinase and cyclin-dependent kinase (CDK), and are useful for cell proliferative diseases such as cancer
02/01/2011US7879886 such as N-benzyl-N-hydroxy-2-(3-hydoxypyridin-2-ene)-1,3-thiazolidine-4-carboxamide, used for reducing the population of Plasmodium in a human infested with Plasmodium protozoans and suffering from malaria
02/01/2011US7879885 Thioalkeneamides as transketolase inhibitors
02/01/2011US7879884 Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
02/01/2011US7879882 Thiazolyl mglur5 antagonists and methods for their use
02/01/2011US7879881 Piperidinyl compounds that selectively bind integrins
02/01/2011US7879880 Substituted aniline derivatives useful as histamine H3 antagonists
02/01/2011US7879879 Biphenyl derivatives
02/01/2011US7879878 Quinolone derivative or salt thereof
02/01/2011US7879877 Carbostyril derivatives for accelerating salivation
02/01/2011US7879876 Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
02/01/2011US7879875 such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects
02/01/2011US7879874 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis
02/01/2011US7879873 Chemotactic Cytokine Receptor 1 (CCR1) antagonists such as 1-(4-Fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (5-methylamino-1,3,4-thiadiazol-2-ylmethyl)-amide, useful for treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis
02/01/2011US7879872 Compositions comprising multiple bioactive agents, and methods of using the same
02/01/2011US7879871 Crystalline forms of tiotropium bromide
02/01/2011US7879870 Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
02/01/2011US7879869 Drugs for ameliorating postcibal hyperglycemia
02/01/2011US7879868 Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
02/01/2011US7879867 Crystalline antifungal compounds
02/01/2011US7879866 Without stimulating calcium influx into cells; using such as N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide
02/01/2011US7879865 central nervous system disorders; brain cancer; oral administration
02/01/2011US7879864 Substituted 8-aminoalkoxy-xanthine compounds and compositions useful in the treatment of hyperlipidemia and diabetes
02/01/2011US7879863 Aniline derivatives
02/01/2011US7879862 Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants
02/01/2011US7879861 4-N-(3-bromophenyl)-6-N-(2-chloroethyl)quinazoline-4,6-diamine, capable of both inhibiting epidermal growth factor receptors and damaging DNA; antitumor and antiproliferative agents
02/01/2011US7879860 Variations in melting points, hygroscopicities, solubilities, flow properties and/or thermodynamic stabilities
02/01/2011US7879859 Diagnosis and treatment of type 2 diabetes and other disorders
02/01/2011US7879858 Substituted tetrahydropyrrolopyrazine compounds and the use thereof in pharmaceutical compositions
02/01/2011US7879857 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
02/01/2011US7879856 Diaminothiazoles useful as Axl inhibitors
02/01/2011US7879855 administering (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide, for the treatment of cancers of the colon, lung, ovary, and pancreas; anticarcinogenic agents
02/01/2011US7879854 2-morpholin-4-ylethyl 5-[3-[(2S)-1-[4-(1-hydroxyhexyl)phenyl]-5-oxopyrrolidin-2-yl]propyl]thiophene-2-carboxylate, useful in treating vision defects, inflammatory bowel disease and alopecia
02/01/2011US7879853 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
02/01/2011US7879852 Melanocortin receptor agonists
02/01/2011US7879851 Viral polymerase inhibitors
02/01/2011US7879850 Organic compounds
02/01/2011US7879849 such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases
02/01/2011US7879848 Dipeptidyl Peptidase-IV inhibiting compounds, method of preparing the same, and pharmaceutical compositions containing the same as an active agent
02/01/2011US7879847 such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome
02/01/2011US7879846 Serine hydrolase inhibitors
02/01/2011US7879845 Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
02/01/2011US7879844 Heterocyclic janus kinase 3 inhibitors
02/01/2011US7879843 Benzothiazin-3-one compound and intermediate therefor
02/01/2011US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
02/01/2011US7879841 crystal structured 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one hydrochloride, used for the treatment of angina pectoris, myocardial infarct, and congestive heart failure; bradycardial agents
02/01/2011US7879840 Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders
02/01/2011US7879839 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol
02/01/2011US7879838 Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
02/01/2011US7879837 Therapeutic or prophylactic agent for multiple sclerosis
02/01/2011US7879836 treatment of hyperphagia comprising the administering 1-(3-chlorophenyl)-3-alkylpiperazine derivatives such as 1-(3-chlorophenyl)-3-ethylpiperazine; anorexigenic agents
02/01/2011US7879835 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyactylate derivatives
02/01/2011US7879834 Spiroindoline modulators of muscarinic receptors
02/01/2011US7879833 comprising a fixed combination of active compounds consisting of the active compound ciclesonide or an epimer thereof and the active compound R,R-formoterol or a salt, in an administration form suitable for inhalative administration by means of a powder inhaler; treatment of bronchitis, asthma
02/01/2011US7879832 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
02/01/2011US7879831 Enhanced drug delivery in transdermal systems
02/01/2011US7879830 Hormone replacement composition and method
02/01/2011US7879829 19-nor-vitamin D analogs with 1,2-dihydrofuran ring
02/01/2011US7879828 Carbohydrate, and an acid or buffer; improved stability in both solid and solution states
02/01/2011US7879827 such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer
02/01/2011US7879826 N-methyl-D-aspartate (NMDA) receptor antagonists, such as Diethyl 3,3'-[({2-[8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl]ethyl}phosphoryl)bis(oxy)]dibenzoate, used for treating pain in a mammals; analgesics
02/01/2011US7879825 N-methyl-D-aspartate (NMDA) receptor antagonists, such as 3-{2-[8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl]ethyl)-3-oxido-7-oxo-7-phenyl-2,4,6-trioxa-3-phosphahept-1-yl benzoate, used for treating pain ; analgesics
02/01/2011US7879824 Administering oligosaccarhides, polysaccharides, and/or glycoaminoglycans for treatment of diseases/conditions associated with allergies, autoimmunity, the adhesion cascade, or metastasis
02/01/2011US7879822 form a complex between sulforaphane, or analog thereof, and cyclodextrin
02/01/2011US7879821 Method for modulating inflammatory responses by altering plasma lipid levels
02/01/2011US7879820 Opalescent mixtures of water, surfactants and cyclodextrins, used as shampoo, bleaches, hair conditioners or dyes
02/01/2011US7879818 biodegradability; stable in aqueous media, may be used as detergents and additives for pharmaceutical compositions for drug delivery, DNA carrier system; biopolymers for controlled release, super-absorbent materials and biomaterials like enzyme immobilization
02/01/2011US7879817 Non-steroidal anti-inflammatory drugs bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region and disease-modifying anti-rheumatic drugs; salicylic acid, aspirin, mefenamic acid, tolfenamic acid; arthritis, suppress inflammation and pain; parenteral, topical
02/01/2011US7879816 Methods of treating cancer and other conditions or disease states using LFMAU and LDT
02/01/2011US7879815 Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
02/01/2011US7879814 Administering adenosine 5'-monophosphate; side effect reduction
02/01/2011US7879813 Interfering RNA delivery system and uses thereof
02/01/2011US7879811 Formulations comprising antisense nucleotides to connexins
02/01/2011US7879810 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
02/01/2011US7879809 Controlling ectoparasite infestations in aquaculture; adding spinosyn component to feed
02/01/2011US7879808 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient